British-Swedish drug maker has gone from Beijing’s scrutiny to its praise, hailed as a sign of doing business in China.
Monday 13 October 2025
scmp - 7 month ago
After China probe, is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms?

⁞
